β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
1. A compound of the formula
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising an effective therapeutic amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , in an oral dosage form.
4. The pharmaceutical composition of claim 3 , wherein the oral dosage form is a solid dosage form.
5. The pharmaceutical composition of claim 4 , wherein the solid dosage form is a tablet.
6. The pharmaceutical composition of claim 4 , wherein the solid dosage form is a capsule.
7. The pharmaceutical composition of claim 3 , wherein the oral dosage form is a liquid dosage form.
8. The pharmaceutical composition of claim 7 , wherein the liquid dosage form is a suspension or solution.
9. The pharmaceutical composition of claim 2 , in an intravenous formulation.
10. The pharmaceutical composition of claim 2 , in a parenteral formulation.
11. A compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
12. The compound of claim 11 , wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
13. The compound of claim 11 , wherein the compound is at least 99% free of the opposite phosphorus S-enantiomer.
14. A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula
or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
15. The pharmaceutical composition of claim 14 , wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
16. The pharmaceutical composition of claim 14 , wherein the compound is at least 99% free of the opposite phosphorus S-enantiomer.
17. The pharmaceutical composition of claim 14 , in an oral dosage form.
18. The pharmaceutical composition of claim 17 , wherein the oral dosage form is a solid dosage form.
19. The pharmaceutical composition of claim 18 , wherein the solid dosage form is a tablet.
20. The pharmaceutical composition of claim 18 , wherein the solid dosage form is a capsule.
21. The pharmaceutical composition of claim 17 , wherein the oral dosage form is a liquid dosage form.
22. The pharmaceutical composition of claim 21 , wherein the liquid dosage form is a suspension or solution.
23. The pharmaceutical composition of claim 14 , in an intravenous formulation.
24. The pharmaceutical composition of claim 14 , in a parenteral formulation.